Atara Biotherapeutics Inc. (NASDAQ:ATRA) concluded the trading at $3.59 on Wednesday, September 21 with a fall of -5.53% from its closing price on previous day.
Taking a look at stock we notice that its last check on previous day was $3.80 and 5Y monthly beta was reading 1.49 with its price kept floating in the range of $3.58 and $3.90 on the day. Considering stock’s 52-week price range provides that ATRA hit a high price of $20.04 and saw its price falling to a low level of $2.83 during that period. Over a period of past 1-month, stock came subtracting -14.11% in its value.
With its current market valuation of $394.11 million, Atara Biotherapeutics Inc. is set to declare its quarterly results on Feb 28, 2022 – Mar 04, 2022. Analysts are in estimates of -$0.93 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to -$3.53 for 2022 with estimates of that growing to -$2.82 in next year. These estimates are suggesting current year growth of 2.80% for EPS and 20.10% growth next year.
Analysts watching the company’s growth closely have provided estimates for its revenue growth with an average revenue estimate of $6.84 million. The average estimate is representing an increase of 76.70% in sales growth from that of posted by the company in the same quarter of last year. In keeping analyst consensus estimate with, company is forecasted to be making an annual revenue of $56.84 million in 2022, which will be 179.40% more from revenue generated by the company last year.
In last 7 days, analysts came adjusting their opinions about stock’s EPS with no upward and no downward revisions, an indication which could give clearer idea about the company’s short term price movement. In contrast, when we review ATRA stock’s current outlook then short term indicators are assigning it an average of 50% Sell, while medium term indicators are categorizing the stock at an average of 100% Sell. Long term indicators are suggesting an average of 100% Sell for it.
According to ratings assigned by 10 analysts at the scale of 1 to 5 with 1.00 representing a strong buy and 5.00 suggesting a strong sell; 2 of them are recommending Atara Biotherapeutics Inc. (ATRA) as a Hold, while 6 are in view that stock is a Buy. Recommendation by 0 analysts for the stock is an Underweight while number of those analysts who rated the stock as an Overweight is 0, whereas 2 of them are considering the stock as a Sell. When taken as whole, stock gets a rating of Overweight and that encourages the investors to exploit the opportunity and build their stake up in the company.
Digging deeper we become aware of the PEG ratio of the ATRA stock which is currently positioned at 0. It further provides that stock’s current price level is -17.41% away from its 20-day simple moving average and is -14.09% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 37.31 while volatility remained at 9.73% over the past week which changes to 8.05% when measuring it over the past month. Beta is valued at 0.92, while measure of average true range or ATR is currently at 0.38.
In comparing Atara Biotherapeutics Inc. (ATRA)’s stock with other industry players reveals that stock’s current price change of -5.53% and that of -78.08% over the past 12 months is in competing position with that of Applied Genetic Technologies Corporation (AGTC) which saw its stock price fall by -6.75% in the last trading and went through a decrease of -90.00% in past 12-month trading. Industry’s another major player Affimed N.V. (AFMD) has fall -3.35% down in previous session, but over the past year has faced a fall of -68.39%, while ImmunoGen Inc. (IMGN) was also down -6.35% however its price remained floating in the red at -20.40% over the same period. Atara Biotherapeutics Inc. has a P/E ratio of 0. On the other hand, the S&P 500 Index was down -1.71% in the last trading session while the Dow Jones Industrial closed the session lower at -1.70%.
Having a second look at Atara Biotherapeutics Inc. (NASDAQ:ATRA) provides that stock’s average daily trading volume for 3 months was 2.65 million, while it jumped to 2.22 million when we calculate an average volume for past 10 days. Number of outstanding shares of the stock stood at 101.60 million.
The figures also indicate that as of Jul 14, 2022, number of stock’s short shares was 8.04 million which implies a short ratio of 3.35. This shows down a 8.61% of Short Interest in company’s outstanding shares on the day. In July the standing of shares short improved as it was 11.27 million in the previous month. Subtraction of -77.22% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.